Floatz logo

Talzenna

Locally Advanced Gastric Carcinoma

National Cancer Institute (NCI)Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

64 Active assets in the Locally Advanced Gastric Carcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Boehringer Ingelheim
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Mayo Clinic
Phase 3BB
TRASTUZUMAB
Boehringer Ingelheim
Phase 2BB
Eloxatin
Shanghai Zhongshan Hospital
Phase 3BB
Capecitabine
Shanghai Zhongshan Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Talzenna is also rated in:

BRCA2-related cancer predispositionDormant
BB
Indicative ·
68 / 100
View asset →
castration-resistant prostate carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →